focus -WSS

focus

author：leisure time 2025-09-28 01:38:06 - browse：9

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Report: NIH

WSS

Health insurers say they are turning to AI to cut costs, improve care

Akili, maker of video game for ADHD, to be acquired for 34 million

Report: NIH

Stigma and the return of syphilis

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

hotspot

focus

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Stigma and the return of syphilis

Psychedelics group wrestles with new pharma identity

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Apple is now the first public company to be valued at $3 trillion

Louisiana bill approved classifying abortion pills as controlled substances

FDA approval of Sarepta Duchenne genetic therapy gives me hope

iTeos Therapeutics debuts first data on TIGIT

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

focus

Health insurers say they are turning to AI to cut costs, improve care

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

iTeos Therapeutics debuts first data on TIGIT

Clinicians often fail to acknowledge the pain caused by long Covid

Pharma’s losing bet in New Jersey

Stroke rates rising, especially in working

knowledge

hotspot

hotspot

focus